To the Editor.—
The article in the September 4, 1987, issue of JAMA entitled "Increased Seizure Frequency With Generic Primidone"1 is an example of incomplete reporting.
The article is a detailed clinical description of the poor response of one patient to administration of primidone (Bolar Pharmaceutical Co Inc, Copiague, NY) for the control of epileptic seizures.
In response to an Adverse Reaction Report (concerning the foregoing) submitted to the Food and Drug Administration, an investigation was carried out at The Cleveland (Ohio) Clinic.
The results of the Food and Drug Administration inspection clearly indicate that there was no evidence of generic failure since this patient responded poorly to both the generic and the trade name products. To quote from the Food and Drug Administration memorandum (Alan B. Lisook, MD, chief, Clinical Investigations):
Dr C. E. Pippenger, who submitted the ADR report, was a coauthor of an article in JAMA titled
. . . [Full Text PDF of this Article]
